Targeting Chemoprophylaxis in Venous Thromboembolism Using Biomarker Guidance

Michael H Cutrone¹, Ian J Welsby^{1

2}, Kamrouz Ghadimi¹

Affiliations

¹ Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina.
² Department of Medicine (Hematology), Duke University School of Medicine, Durham, North Carolina.

Comment

Michael H Cutrone et al. JAMA Surg. 2023.

. 2023 Feb 1;158(2):220-221.

doi: 10.1001/jamasurg.2022.5333.

Michael H Cutrone¹, Ian J Welsby^{1

2}, Kamrouz Ghadimi¹

¹ Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina.
² Department of Medicine (Hematology), Duke University School of Medicine, Durham, North Carolina.

No abstract available

Comment in

Targeting Chemoprophylaxis in Venous Thromboembolism Using Biomarker Guidance-Reply.
Cotton BA, Cardenas JC. Cotton BA, et al. JAMA Surg. 2023 Feb 1;158(2):221-222. doi: 10.1001/jamasurg.2022.5336. JAMA Surg. 2023. PMID: 36416852 No abstract available.

Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism.
Vincent LE, Talanker MM, Butler DD, Zhang X, Podbielski JM, Wang YW, Chen-Goodspeed A, Hernandez Gonzalez SL, Fox EE, Cotton BA, Wade CE, Cardenas JC. Vincent LE, et al. JAMA Surg. 2022 Aug 1;157(8):713-721. doi: 10.1001/jamasurg.2022.2214. JAMA Surg. 2022. PMID: 35731524 Free PMC article.